KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $38.85 $43.55 Friday, 26th Apr 2024 XENE stock ended at $40.50. This is 1.00% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 2.36% from a day low at $39.80 to a day high of $40.74.
90 days $38.85 $50.99
52 weeks $27.99 $50.99

Historical Xenon Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Apr 26, 2024 $40.02 $40.74 $39.80 $40.50 312 186
Apr 25, 2024 $39.33 $40.82 $38.85 $40.10 245 032
Apr 24, 2024 $41.16 $41.16 $39.24 $39.50 315 251
Apr 23, 2024 $40.23 $41.59 $40.05 $41.09 311 522
Apr 22, 2024 $39.92 $40.31 $39.18 $40.01 226 986
Apr 19, 2024 $40.48 $41.26 $39.01 $39.88 356 346
Apr 18, 2024 $41.72 $41.72 $39.59 $40.31 313 122
Apr 17, 2024 $41.49 $41.99 $41.21 $41.63 300 188
Apr 16, 2024 $41.31 $42.03 $41.00 $41.49 319 504
Apr 15, 2024 $41.33 $41.71 $40.62 $41.31 362 007
Apr 12, 2024 $42.67 $42.67 $40.54 $41.30 499 214
Apr 11, 2024 $42.36 $43.09 $42.14 $42.97 180 244
Apr 10, 2024 $42.58 $43.26 $41.99 $42.43 196 674
Apr 09, 2024 $42.58 $43.09 $42.47 $43.03 200 074
Apr 08, 2024 $42.25 $42.79 $41.75 $42.62 259 916
Apr 05, 2024 $42.04 $42.78 $41.48 $42.25 177 053
Apr 04, 2024 $41.50 $42.68 $41.36 $42.21 272 880
Apr 03, 2024 $41.47 $41.75 $40.97 $41.30 242 746
Apr 02, 2024 $41.85 $42.01 $41.14 $41.47 229 980
Apr 01, 2024 $43.18 $43.18 $41.26 $42.14 233 884
Mar 28, 2024 $42.88 $43.55 $42.38 $43.05 307 762
Mar 27, 2024 $42.76 $43.19 $42.08 $43.00 433 170
Mar 26, 2024 $43.00 $43.52 $42.59 $42.66 181 822
Mar 25, 2024 $43.97 $44.47 $42.51 $42.70 398 787
Mar 22, 2024 $43.66 $44.15 $43.20 $44.00 263 744
Click to get the best stock tips daily for free!

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o... XENE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT